MaxCyte, Inc.
Every calculator, already run for MXCT
Open the full toolkit →You have the numbers on MXCT. Get the argument.
A written report on which of these readings actually decide the outcome for MaxCyte, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
6 analysts covering MXCTAnalyst Price Target Disagreement for MaxCyte, Inc.
Wall Street's bull case implies +329% from the current price; the bear case implies +109%. A 221% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MXCT
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electropo…
MXCT — frequently asked
Is MXCT a buy right now?
Wall Street's consensus rating on MaxCyte, Inc. is none across 6 analysts, with a mean price target of $4.11 (+253% vs. the current $1.17). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is MXCT's next earnings date?
MaxCyte, Inc. is next scheduled to report earnings around Nov 11, 2026. A full MXCT research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for MaxCyte, Inc.?
Analysts covering MaxCyte, Inc. (MXCT) range from a bear-case target of $2.43 to a bull-case high of $5.00, with a mean consensus target of $4.11 across 4 analysts. The spread of $2.57 (221% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare MaxCyte, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For MaxCyte, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MXCT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on MaxCyte, Inc., in minutes. 3 free reports included with every account — no credit card required.